Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Aug. 12, 2022 4:58 PM ETInhibikase Therapeutics, Inc. (IKT)By: Pranav Ghumatkar, SA News Editor
  • Inhibikase Therapeutics press release (NASDAQ:IKT): Q2 GAAP EPS of -$0.18.
  • Revenue of $6.55K (-99.5% Y/Y).
  • Cash and cash equivalents were $32.2 million as of June 30, 2022.
  • The Company expects that existing cash and cash equivalents will be sufficient to fund its normal operations and capital expenditure requirements through December 31, 2023.
  • Shares -2.73%.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.